About Us

GlobeMed Pharma Group: Innovating Cannabis-Based Pharmaceuticals

GlobeMed Pharma Group is a privately owned corporation with controlling interests in cannabis cultivation operations in Santa Marta, Colombia, and Blantyre, Malawi. These locations were strategically chosen for their optimal climates, fertile soils, and access to skilled agricultural labor, which collectively enhance the quality and efficiency of our cultivation processes. Our two main production facilities, Sativa Nativa SAS and Nexgen Medical Limited, are designed to meet the highest standards in the production of cannabis-based active pharmaceutical ingredients (API) for the pharmaceutical industry.

While our operations are diverse, they share common management, operating procedures, and the same genetically advanced cannabis cultivars that are grown exclusively within our owned and operated facilities. All of our cultivation facilities are GACP certified, undergoing rigorous annual audits to ensure a safe and compliant environment for both our employees and the pharmaceutical products we produce. Our Swiss manufacturing facility adheres to EudraGMP, Swiss GMP, and EU Pharmacopoeia standards, ensuring the highest level of compliance for global pharmaceutical markets.

Our Facilities and Operations

Sativa Nativa SAS

Sativa Nativa SAS is focused on indoor controlled cannabis flower production, utilizing intellectual property around proprietary growing protocols developed since 2016. Originally designed as a research and development location for advancing cannabis genetics, Sativa Nativa boasts a vast seed bank that ensures consistent, high-quality flower production year after year. Our cultivation process uses the “seed-to-sale” traceability system, which is essential for maintaining the integrity of our API program in Switzerland.

By January 30, 2025, Sativa Nativa will be producing 3,000 kg of premium dried flower per month, all packaged in EU GMP-approved pharmaceutical-grade packages. We exclusively use this flower for extraction at our Swiss facilities, ensuring that each batch meets our rigorous quality standards.

Nexgen Medical Limited

Nexgen Medical Limited operates on 800 hectares of certified organic land in Malawi, which is fully irrigated and equipped with state-of-the-art water treatment systems. Our innovative growing technology allows for a 30-day crop rotation, producing 100,000 to 150,000 kg of dried flower per month, all of which is naturally organic and pesticide-free. This system integrates advanced irrigation and nutrient delivery methods, ensuring optimal plant growth and consistent quality. By leveraging cutting-edge agricultural techniques, we differentiate ourselves from competitors through higher efficiency, reduced environmental impact, and the ability to scale production while maintaining strict organic standards. This large-scale operation ensures that we maintain a consistent supply of high-quality product for API extraction.

The entire facility is currently GACP certified and undergoing significant transformations to achieve full EU GMP and Swiss GMP certification by August 2025. Historically, Nexgen Medical Limited has successfully sent over 14,000 kg of flower into the European market for extraction. With ongoing enhancements, we aim to meet the growing global demand for high-quality, cannabis-based medicines.

 Commitment to Quality

At GlobeMed Pharma Group, we are deeply committed to producing consistent, high-quality cannabis-based medicines that comply with the most stringent pharmaceutical standards. Our cultivation facilities are GACP certified, ensuring that all cultivation processes meet stringent standards for quality and safety. Additionally, our Swiss manufacturing facility is compliant with EudraGMP, which governs Good Manufacturing Practices within the European Union, Swiss GMP, and EU Pharmacopoeia standards, ensuring the highest level of compliance for pharmaceutical-grade products. Our entire cultivation, quarantine, drying, and packaging process is validated by our dedicated Quality Assurance Team, ensuring that all products meet the necessary regulatory requirements.

Key features of our facilities and processes include:

• Certified organic land at Nexgen Medical Limited, with full irrigation and state-of-the-art water treatment to comply with EU Pharmaceutical Regulations.
• No pesticide use in our cultivation processes, ensuring that all products are naturally organic.
• GACP certification for all facilities, transitioning to EU GMP and Swiss GMP certification by August 2025.
• A highly innovative growing technology that allows for rotating crops every 30 days, with a minimum THC content of 20% up to 30% in our API-focused strains.
• Custom strains developed from our extensive registered seed bank.
• Full seed-to-sale traceability, ensuring that all flower produced at Sativa Nativa and Nexgen undergoes rigorous quality control.
• Compliance with EU Pharmacopoeia and other key pharmaceutical regulations, as outlined below:
  • Pharmacopoeia Europaea (Ph. Eur.)
  • Pharmacopoeia Helvetica (Ph. Helv.)
  • German Pharmacopoeia (DAB)
  • Medicinal Products Act (HMG)
  • German Medicines Codex (DAC-NRF)

Processes: Ensuring Excellence

Achieving the highest quality cannabis-based products requires more than just skilled personnel and a solid quality management system; it also depends on well-constructed infrastructure and optimal processes. At GlobeMed Pharma Group, we have invested in advanced infrastructure and proprietary processes developed in collaboration with leading manufacturers from Europe and North America. These processes are key to ensuring that our products meet the most stringent quality standards.

The extraction process is one of the most critical steps, and not all methods produce the same quality results. At GlobeMed Pharma Group, we carefully define and continuously monitor all critical process parameters. For our API-focused strains with a THC content of 20-30%, we utilize a solventless extraction process to ensure the highest purity and quality. This method eliminates the use of chemical solvents, preserving the natural integrity of the cannabinoids and minimizing the risk of contaminants, resulting in a safer, cleaner, and more effective final product. These factors strongly influence the final product’s quality, and we ensure that every step is optimized for the best results. We use custom-built systems designed specifically for our products, ensuring maximum efficiency and quality control.

Primary Process Steps

The following primary process steps are carried out at GlobeMed Pharma Group to ensure the highest level of product quality:

• Maceration/Percolation
• Distillation
• Crystallization
• Analytics and Quality Control
• Drying
• Dry Extraction
• Formulations
• Primary
• Packaging
• Secondary Packaging
• Shipping

Our comprehensive process is designed to meet EU GMP and Swiss GMP standards, and each critical component is qualified and validated based on its potential impact on product quality and safety.

Driving Innovation and Patient Care

GlobeMed Pharma Group is not only focused on scaling production but also on developing genetically advanced cannabis strains that have increased cannabinoid content. We are actively researching and producing novel cannabinoid derivatives that can offer improved therapeutic molecular structures for better health outcomes. This work is at the forefront of the cannabis pharmaceutical industry, as we aim to bring new, effective treatments to patients in need worldwide.

Our commitment to the clinical study and validation of our products ensures that we are continuously improving the therapeutic potential of our cannabis-based medicines. For example, GlobeMed has pioneered the use of solventless extraction processes for API-focused strains, significantly enhancing product purity and environmental sustainability. Additionally, we have developed advanced genetic research programs to create cannabinoid derivatives with improved therapeutic efficacy. It is our ethical responsibility to remain diligent in developing the best possible products to improve the health and well-being of patients globally.